Product How it works Pricing Blog FAQ About Contact
Allogene Therapeutics

Allogene Therapeutics (NASDAQ: ALLO) revenue

Allogene Therapeutics reported revenue of $2.6m for fiscal 2025, 2,500.0% more than in fiscal 2024 ($0.1m).

Allogene Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 7 was fiscal 2021. The biggest drop was in fiscal 2022, −99.9%.

Revenue, in millions of US dollars0.020190.02020114.120210.220220.120230.120242.62025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$2.6m+2,500.0%−$209.3m−8,050.6%
2024$0.1m+5.3%−$273.2m−273,199.0%
2023$0.1m−39.1%−$327.7m−344,986.3%
2022$0.2m−99.9%−$335.5m−215,087.2%
2021$114.1m—−$180.2m−157.9%
2020$0.0m—−$258.2m—
2019$0.0m—−$202.0m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Allogene Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Allogene Therapeutics ranks 392nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Allogene Therapeutics, 2,500.0%.

RankCompanyRevenueRevenue growth
390thAbsci$2.8m−38.2%
391stCartesian Therapeutics$2.8m−92.8%
392ndAllogene Therapeutics$2.6m2,500.0%
393rdOramed Pharmaceuticals$2.0m—
394thCelldex Therapeutics$1.5m−78.0%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Allogene Therapeutics

How much revenue did Allogene Therapeutics make in fiscal 2025?
Allogene Therapeutics reported revenue of $2.6m for fiscal 2025, compared with $0.1m in fiscal 2024.
What was the best year for revenue at Allogene Therapeutics?
Of its last 7 fiscal years, fiscal 2021, with $114.1m.
Where does Allogene Therapeutics rank in its sector by revenue?
It ranks 392nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Allogene Therapeutics come from?
From the annual report (Form 10-K) that Allogene Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Allogene Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Allogene Therapeutics: the Allogene Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.